<DOC>
	<DOCNO>NCT00927914</DOCNO>
	<brief_summary>The purpose study determine effect 40 mg 80 mg ranirestat peroneal motor nerve conduction velocity relative placebo subject mild moderate diabetic sensorimotor polyneuropathy .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Oral Ranirestat ( 40 80 mg ) Mild Moderate Diabetic Sensorimotor Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<criteria>Subjects Type 1 Type 2 , insulindependent non insulindependent diabetes mellitus . Subjects history distal symmetric polyneuropathy , secondary diabetes , diagnose accordance American Academy Neurology criterion . Female subject , nonreproductive potential ( &gt; =12 month postmenopausal surgically sterile ) use adequate contraception include abstinence double barrier method ( diaphragm condom spermicidal cream , intrauterine device condom spermicidal cream ) . Male subject partner childbearing potential must also use adequate contraception . Subjects must able read , understand , provide write informed consent enrol study screen . History diabetic foot ulcer low extremity amputation . Diabetic amyotrophy nondiabetic cause lower limb neuropathy/neuropathic symptom . Clinically significant illness , opinion investigator , would compromise subject 's suitability participate study reason safety would confound efficacy assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>